4//SEC Filing
FRIEDMAN JOHN H 4
Accession 0000914190-12-000062
CIK 0001180145other
Filed
Jan 31, 7:00 PM ET
Accepted
Feb 1, 6:05 PM ET
Size
26.0 KB
Accession
0000914190-12-000062
Insider Transaction Report
Form 4
FRIEDMAN JOHN H
Director
Transactions
- Sale
Common Stock
2012-02-01$9.18/sh−5,796$53,189→ 65,675 total(indirect: Easton Hunt Capital Partners, L.P.) - Sale
Common Stock
2012-01-30$9.24/sh−29,932$276,706→ 89,734 total(indirect: Easton Hunt Capital Partners, L.P.) - Sale
Common Stock
2012-01-31$9.20/sh−18,263$168,104→ 71,471 total(indirect: Easton Hunt Capital Partners, L.P.)
Holdings
- 421,023(indirect: Easton Capital Partners, LP)
Common Stock
- 15,088
Stock Option (right to buy)
Exercise: $11.38Exp: 2017-11-12→ Common Stock (15,088 underlying) - 4,321
Stock Option (right to buy)
Exercise: $7.90Exp: 2017-10-08→ Common Stock (4,321 underlying) - 11,628
Restricted Stock Units
→ Common Stock (11,628 underlying) - 7,192
Restricted Stock Units
→ Common Stock (7,192 underlying) - 107,833(indirect: Easton Hunt Capital Partners, L.P.)
Warrant (Right to Buy)
Exercise: $9.28From: 2008-09-12Exp: 2013-09-12→ Common Stock (107,833 underlying) - 38,820
Stock Option (right to buy)
Exercise: $8.83Exp: 2016-08-14→ Common Stock (38,820 underlying) - 8,000
Common Stock
- 21,739
Restricted Stock Units
→ Common Stock (21,739 underlying) - 151,617(indirect: Easton Hunt Capital Partners, L.P.)
Warrant (Right to Buy)
Exercise: $8.83From: 2009-02-25Exp: 2014-02-24→ Common Stock (151,617 underlying) - 151,617(indirect: Easton Capital Partners, LP)
Warrant (Right to Buy)
Exercise: $8.83From: 2009-02-25Exp: 2014-02-24→ Common Stock (151,617 underlying) - 5,714
Restricted Stock Units
→ Common Stock (5,714 underlying)
Footnotes (9)
- [F1]The sale of the underlying shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Easton Hunt Capital Partners, L.P. on November 30, 2011.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.13 to $9.51 inclusive. The reporting person undertakes to provide Cardiovascular Systems, Inc., any security holder of Cardiovascular Systems, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.13 to $9.28 inclusive. The reporting person undertakes to provide Cardiovascular Systems, Inc., any security holder of Cardiovascular Systems, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.28 inclusive. The reporting person undertakes to provide Cardiovascular Systems, Inc., any security holder of Cardiovascular Systems, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]Mr. Friedman disclaims beneficial ownership of shares held by Easton Hunt Capital Partners, L.P. and Easton Capital Partners, LP except to the extent of his pecuniary interest therein.
- [F6]Fully exercisable.
- [F7]Each restricted stock unit represents the right to receive a payment from CSI equal in value to the market price per share of CSI common stock on the date of payment and shall be payable in shares of the Company's Common Stock beginning six months following the termination of each director's board membership.
- [F8]Each restricted stock unit represents the right to receive a payment from CSI equal in value to the market price per share of CSI common stock on the date of payment, and shall be payable in cash or shares of the Company's Common Stock beginning six months following the termination of each director's board membership; provided, however, that the restricted stock units vest in remaining quarterly amounts of 1,798 on each of 3/31/2012 and 6/30/2012.
- [F9]Mr. Friedman disclaims beneficial ownership of warrants held by Easton Hunt Capital Partners, L.P. and Easton Capital Partners, LP except to the extent of his pecuniary interest therein.
Documents
Issuer
Cardiovascular Systems Inc
CIK 0001180145
Entity typeother
Related Parties
1- filerCIK 0001067915
Filing Metadata
- Form type
- 4
- Filed
- Jan 31, 7:00 PM ET
- Accepted
- Feb 1, 6:05 PM ET
- Size
- 26.0 KB